Organization | Serono

Serono Report issue

Contributed to NME For profit Phase 3

Founded: Geneva Switzerland (1906)

Status: Acquired by Merck KGaA (2006) → now Merck Serono (2006)

Organization Overview

First Clinical Trial

2002

NCT00249860

First Marketed Drug

1975

lutropin alpha (luveris)

First NDA Approval

1976

somatropin (protropin)

Last Known Activity

2006

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Active Ingredients

Marketed Drugs (7)

follitropin alfa (Gonal-F) (NDA)

interferon beta-1a (Avonex) (2002)

interferon beta-1b (betaseron) (2002)

lutropin alpha (luveris) (2004 NDA)

mitoxantrone (novantrone) (2000)

somatropin (protropin) (1976 NDA)

urofollitropin (Metrodin) (1986 NDA)

Drugs in Phase 3 Trials (7)

human choriogonadotropin alfa (hCG) (1 trial)

interferon beta-1b (betaseron) (1 trial)

naltrexone (revia) (1 trial)

omega-3 fatty acids (Omacor) (1 trial)

peginterferon beta-1a (Plegridy) (1 trial)

progesterone (progestasert) (1 trial)

ribavirin (virazole) (1 trial)

Indications

Approved Indications

Dwarfism, Pituitary

HIV Infections

Infant, Small for Gestational Age

Prader-Willi Syndrome

Renal Insufficiency, Chronic

Short Bowel Syndrome

Turner Syndrome

Experimental Indications (Clinical Trials, Phases 1-4)

Encephalomyelitis (Phase 3)

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Hepatitis C (Phase 3)

Hepatitis C, Chronic (Phase 3)

Hepatitis, Chronic (Phase 3)

Infertility (Phase 3)

Macular Edema (Phase 3)

Multiple Sclerosis (Phase 3)

Multiple Sclerosis, Relapsing-Remitting (Phase 3)

Pars Planitis (Phase 3)

Sclerosis (Phase 3)

Uveitis (Phase 3)

Uveitis, Intermediate (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 5
# of Trial APIs: 7